CMPXCompass TherapeuticsFinished
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer · Colon Cancer · Rectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 49 (final count)
- Started
- Dec 8, 2022
- Main results expected
- May 15, 2025
- Fully finished
- May 15, 2025
- Results posted
- Jul 28, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05513742 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC